Susquehanna Fundamental Investments, LLC Bei Gene, Ltd. Transaction History

Susquehanna Fundamental Investments, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$125.51 - $229.3 $417,697 - $763,110	-3,328 Reduced 33.13%	6,718 $1.48 Million
Q1 2022 May 16, 2022	BUY	$146.52 - $269.56 $1.47 Million - $2.71 Million	10,046 New	10,046 $1.9 Million
Q4 2021 Feb 14, 2022	SELL	$248.56 - $389.34 $1.41 Million - $2.21 Million	-5,670 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$249.6 - $403.14 $1.42 Million - $2.29 Million	5,670 New	5,670 $2.06 Million

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.